Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina

Longueira, Yésica; Polo, María L.; Turk, Gabriela; Laufer, Natalia

doi:10.1101/2021.01.31.21250167

Cited by 2 publications

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort

Blanco

Konigheim

Díaz

et al. 2022

Vaccine

View full text Add to dashboard Cite

We evaluated humoral immune-response elicited by Sputnik-V by measuring anti-Spike (S) IgG antibodies (Abs) and neutralizing antibodies (NAb) prior to, 14 and 42 days after-vaccination. The safety and disease rates among vaccinated individuals were also evaluated. Since SARS-CoV-2 lineage P.1 is rapidly spreading in Argentina, virus-neutralizing activity of Sputnik-V-elicited and infection-elicited NAb faced to P.1 were also assessed. A total of 285 participants were recruited; all reported good tolerance, without any severe adverse event. Nine COVID-19 cases were confirmed in fully vaccinated individuals and viable P.1 variant was successfully isolated from one of them. At day 42, 99.65% of the individuals had anti-S IgG; however, 23.15% had not detectable NAbs. Significantly higher neutralization potency against WT compared to P.1 (p<0·001) was observed. Some samples failed to neutralize P.1, mainly among vaccinated-naїve subjects; however, no significant differences were observed among previously infected-vaccinated individuals. Our results corroborated that Sputnik-V is safe and induces an efficient humoral immune response, although not all immunized subjects develop Nabs. Herein, we show for the first time, evidence of infectious SARS-CoV-2 shedding from Sputnik-V fully vaccinated individuals, by the isolation of viable virus from the nasopharyngeal swab of one participant of our study, 139 days after receiving the second dose. Thereby, we provide evidence indicating that the vaccine might avoid severe forms of COVID-19 but does not prevent infection nor prevents transmission from a fully vaccinated individual.

show abstract

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort

Blanco

Konigheim

Díaz

et al. 2022

Vaccine

View full text Add to dashboard Cite

show abstract

Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modeling study

Owusu‐Boaitey

Russell

Meyerowitz-Katz

et al. 2022

Preprint

View full text Add to dashboard Cite

We performed a systematic review and meta-analysis of SARS-CoV-2 serology studies to estimate time-dependent sensitivity for a large set of serological assays. We find that seroreversion depends strongly on the antigen and the analytic technique of the assay. We estimate the average time-varying sensitivity for different types of assays, as defined by their technical characteristics, which can be used to approximate the sensitivity of out-of-sample assays. We find large variability between types of assays, with assays of certain characteristics (nucleocapsid antigen, lateral flow assay) having an average of 20% sensitivity at 6 months, while others (receptor-binding domain antigen, sandwich design) have 98% sensitivity. Importantly, we estimate that almost a third of included assays depart significantly from manufacturer specified sensitivity after 6 months. Our analysis outlines the importance of monitoring the seroreversion of serological tests, and provides a tool for researchers to account for this phenomenon.

show abstract

Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina

Cited by 2 publications

References 50 publications

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort

Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modeling study

Contact Info

Product

Resources

About